PG2

DRUG7 trials

Sponsors

PhytoHealth Corporation, China Medical University Hospital

Conditions

Acute StrokeCancerComplementaryFatigueHemorrhagic StrokeIdiopathic Thrombocytopenic Purpura (ITP)Neoplasm MetastasisNeoplasm Recurrence

Early Phase 1

The Pilot Clinical Study of PG2 Injection on Hemorrhagic Stroke

CompletedNCT01325233

PhytoHealth CorporationHemorrhagic Stroke

Start: 2011-03-31End: 2013-09-30Updated: 2025-06-04

Phase 1

PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

CompletedNCT01696565

PhytoHealth CorporationNeoplasm Metastasis, Neoplasm Recurrence

Start: 2001-12-31End: 2003-10-31Updated: 2025-06-04

Phase 2

Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue

TerminatedNCT00518869

PhytoHealth CorporationComplementary, Fatigue, Quality of Life

Start: 2007-09-30End: 2009-12-31Updated: 2025-06-04

PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care

CompletedNCT00523107

PhytoHealth CorporationFatigue

Start: 2007-08-31End: 2008-04-30Updated: 2025-06-04

Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients

CompletedNCT00860600

PhytoHealth CorporationIdiopathic Thrombocytopenic Purpura (ITP)

Start: 2008-09-30End: 2011-08-31Updated: 2025-06-04

PG2 Injection 500 mg in Acute Stroke Study (Pass)

CompletedNCT01603667

China Medical University HospitalAcute Stroke

Start: 2012-06-30End: 2015-10-31Updated: 2016-11-04

Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer

WithdrawnNCT02077621

PhytoHealth CorporationCancer, Fatigue, Surgery

Start: 2014-02-28End: 2020-12-31Updated: 2025-06-04